BMSSC
RARE icon

B. Metzler seel. Sohn & Co’s Ultragenyx Pharmaceutical RARE Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-12,862
Closed -$296K – 745
2025
Q4 		$296K Sell
12,862
-17,176
-57% -$565K ﹤0.01% 695
2025
Q3 		$904K Hold
30,038
– – 0.01% 560
2025
Q2 		$1.09M Hold
30,038
– – 0.01% 521
2025
Q1 		$1.09M Buy
30,038
+14,581
+94% +$607K 0.01% 502
2024
Q4 		$650K Sell
15,457
-8,360
-35% -$415K 0.01% 613
2024
Q3 		$1.32M Hold
23,817
– – 0.01% 491
2024
Q2 		$979K Hold
23,817
– – 0.01% 527
2024
Q1 		$1.11M Hold
23,817
– – 0.01% 505
2023
Q4 		$1.14M Buy
23,817
+2,737
+13% +$106K 0.01% 478
2023
Q3 		$752K Sell
21,080
-18,414
-47% -$730K 0.01% 520
2023
Q2 		$1.82M Buy
39,494
+21,158
+115% +$981K 0.02% 387
2023
Q1 		$735K Buy
18,336
+1,741
+10% +$74.7K 0.01% 494
2022
Q4 		$769K Buy
16,595
+7,872
+90% +$310K 0.01% 480
2022
Q3 		$361K Sell
8,723
-406
-4% -$20.9K 0.01% 596
2022
Q2 		$545K Sell
9,129
-336
-4% -$20.7K 0.01% 542
2022
Q1 		$687K Buy
+9,465
New +$659K 0.01% 546

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

B. Metzler seel. Sohn & Co's RARE Position: Q1 2026 in Review

B. Metzler seel. Sohn & Co sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2026, closing a stake of 12,862 shares — an estimated $296K sold.

B. Metzler seel. Sohn & Co first reported a position in RARE in Q1 2022 and held it in 16 quarters. The position peaked at $1.82M in Q2 2023. 296 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • B. Metzler seel. Sohn & Co reported no remaining Ultragenyx Pharmaceutical position as of Q1 2026 after selling out during the quarter.
  • B. Metzler seel. Sohn & Co sold 12,862 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $296K.
  • B. Metzler seel. Sohn & Co first reported a position in Ultragenyx Pharmaceutical in Q1 2022 and held it in 16 quarters.
  • B. Metzler seel. Sohn & Co's Ultragenyx Pharmaceutical position peaked at $1.82M in Q2 2023.
  • 296 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q1 2026, filed 8 May 2026.